Literature DB >> 15674748

LINAC radiosurgery in skull base meningiomas.

R Deinsberger1, J Tidstrand, H Sabitzer, G Lanner.   

Abstract

LINAC radiosurgery has provided increasing access and changed treatment strategies in patients with benign skull base meningiomas in recent years. From January 1996 to January 2003, 37 patients with skull base meningiomas were treated with LINAC radiosurgery. A combination of the University of Florida system and the X Knife System, developed by Radionics, was used in all patients. Eight patients were treated by microsurgical resection before radiosurgery, in two patients tumor recurrence was treated and in 29 patients LINAC radiosurgery was the initial treatment procedure. The median treatment volume was 5.9 mL (0.7 to 22 mL) and the median given dose was 14.6 Gy (12.8 to 18 Gy) prescribed to the 80 percent isodose line. The follow-up period is between 12 and 96 months, median 66 months. 12 patients (32.4 %) showed a significant reduction in tumor size, in 11 patients (29.7 %) there was significantly less contrast enhancement and in 13 patients (35.1 %) the skull base meningioma was without any change. In one patient (2.8 %) there was tumor growth 48 months after radiosurgery, so the tumor control rate was 97.2 %. Two patients (5.6 %) showed neurological worsening after radiosurgery, whereas the symptoms were transient in one patient. LINAC radiosurgery offers us an effective treatment modality and changes treatment strategies in skull base meningiomas towards a less aggressive surgical approach. By combining microsurgery and radiosurgery we can achieve high tumor control rates with an acceptable low morbidity and a high level of quality of life.

Entities:  

Mesh:

Year:  2004        PMID: 15674748     DOI: 10.1055/s-2004-830126

Source DB:  PubMed          Journal:  Minim Invasive Neurosurg        ISSN: 0946-7211


  8 in total

Review 1.  Linac radiosurgery as a tool in neurosurgery.

Authors:  R Deinsberger; J Tidstrand
Journal:  Neurosurg Rev       Date:  2005-02-22       Impact factor: 3.042

Review 2.  New prospects for management and treatment of inoperable and recurrent skull base meningiomas.

Authors:  Mahlon D Johnson; Burak Sade; Michael T Milano; Joung H Lee; Steven A Toms
Journal:  J Neurooncol       Date:  2007-07-12       Impact factor: 4.130

3.  LINAC radiosurgery as single treatment in cerebral metastases.

Authors:  R Deinsberger; J Tidstrand
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

4.  Stereotactic radiosurgery: a meta-analysis of current therapeutic applications in neuro-oncologic disease.

Authors:  Susan C Pannullo; Justin F Fraser; Jennifer Moliterno; William Cobb; Philip E Stieg
Journal:  J Neurooncol       Date:  2010-12-09       Impact factor: 4.130

5.  Linear accelerator-based stereotactic radiosurgery of intracranial meningiomas: results of the first 5 years of clinical practice.

Authors:  Osama S Abdelaziz; Alaa Kandil; Shaaban El-Assaal; Amro Abdelaziz; Yosry Rostom; Yaser Rashed
Journal:  Neurosurg Rev       Date:  2010-10-09       Impact factor: 3.042

6.  Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas.

Authors:  Sabrina T Astner; Marilena Theodorou; Mihaela Dobrei-Ciuchendea; Florian Auer; Christine Kopp; Michael Molls; Anca-Ligia Grosu
Journal:  Strahlenther Onkol       Date:  2010-07-29       Impact factor: 3.621

Review 7.  FACT-MNG: tumor site specific web-based outcome instrument for meningioma patients.

Authors:  D Zlotnick; S N Kalkanis; A Quinones-Hinojosa; K Chung; M E Linskey; R L Jensen; F DeMonte; F G Barker; C A Racine; M S Berger; P M Black; M Cusimano; L N Sekhar; A Parsa; M Aghi; Michael W McDermott
Journal:  J Neurooncol       Date:  2010-09-18       Impact factor: 4.130

Review 8.  Radiotherapy and radiosurgery for benign skull base meningiomas.

Authors:  Giuseppe Minniti; Maurizio Amichetti; Riccardo Maurizi Enrici
Journal:  Radiat Oncol       Date:  2009-10-14       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.